What is William Blair’s Forecast for Hologic Q2 Earnings?

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at William Blair decreased their Q2 2025 earnings per share (EPS) estimates for shares of Hologic in a report issued on Thursday, February 6th. William Blair analyst A. Brackmann now expects that the medical equipment provider will post earnings of $1.00 per share for the quarter, down from their previous estimate of $1.07. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share.

Other analysts also recently issued research reports about the company. Royal Bank of Canada decreased their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday, February 6th. Evercore ISI decreased their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research report on Thursday, February 6th. Stephens reissued an “overweight” rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Morgan Stanley dropped their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Ten analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Trading Up 1.0 %

Shares of NASDAQ:HOLX opened at $65.24 on Monday. The company has a current ratio of 3.49, a quick ratio of 3.03 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $14.73 billion, a PE ratio of 20.58, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic has a 1 year low of $63.62 and a 1 year high of $84.67. The firm has a fifty day moving average price of $72.06 and a 200 day moving average price of $77.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%.

Hedge Funds Weigh In On Hologic

Hedge funds have recently made changes to their positions in the business. FMR LLC raised its holdings in shares of Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after buying an additional 2,174,093 shares in the last quarter. Nordea Investment Management AB raised its stake in Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Hologic during the fourth quarter valued at $27,007,000. Swedbank AB boosted its stake in shares of Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after purchasing an additional 306,562 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Hologic by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after purchasing an additional 238,222 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Activity

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.88% of the stock is currently owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.